

A discovery and IP development company, advancing the science behind medical cannabis



Stock Info

Canada CSE: VRT

U.S. OTC: VRTHF

Germany FRT: 2VP

Shares Outstanding 23.99M*

Market Capitalization \$12M*

Fiscal Year End April 30th

(*6/1/2016)

2016 News Highlights

Health Canada Approval Received
Obtained exemption from Health Canada to legally perform cannabis research...

Hires Intellectual Property Law Firm to Protect its New Cannabis Cultivars for Specific Disease Conditions

Hired IP law firm Oyen Wiggs Green & Mutala LLP to oversee the patenting of its new...

Cannevert Therapeutics Ltd. Delivers Scientific Progress Report
Scientific team delivers its first quarterly progress report...

Investor Relations

Contact: Sam Eskandari

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Web: veritaspharmainc.com

About Veritas Pharma


- Solving the critical need for real science to support claims surrounding medical marijuana, developing the most effective cultivars (strains) targeting pain and nausea related to cancer
- Research and commercialization led by strong management and renowned group of scientists
- Low cost research and development model to help drive shareholder value
- Established exclusive partner alliance and investment in high-level R&D arm, Cannevert Therapeutics, bringing together veteran academic pharmacologists, anesthetists & chemists
- Clinical trials to demonstrate real therapeutic utilities, with the potential to deliver the industry's first set of standards
- Speed-to-market employs a whole plant methodology, translating to years faster to market, estimated at one-tenth the time of traditional pharma drug approval
- Scientific and commercial mission is to patent protect IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets

Multi-Billion Dollar Growth Industry

- The medical marijuana market is US\$1.47 billion in North America alone¹
- Forecast 17% annual growth, with market estimated to double in size within 5 years²
- Canada has a national medical cannabis program and a newly elected prime minister who has stated his intention to legalize cannabis on a national level
- 39 states have legalized cannabis in some form for recreational or medicinal use in the U.S. so far

Major Growth Drivers

- Easing regulatory framework and continuing trend towards liberalization of cannabis laws at the national and state levels will help drive the market
- Future innovation and advancement in science related to cannabis therapeutics will accelerate patient adoption and consumption
- Opportunity exists to create new distinguishable products that are clinically tested, supported by real data to be sold or licenced to various markets for medicinal use
- Growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as cannabis. The global opioids market is valued at a staggering US\$34.8bn in 2015³



Leading Management

Dr. Lui Franciosi, PhD – CEO

20+ years experience conducting pharmaceutical and medical device studies in academia and industry. Previously, Chief Operating Officer of Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior, he completed his post-doctoral research in COPD progression modelling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. Obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada — and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

David Alexander, CPA /CA – CFO

Holds a BComm in Finance from The University of British Columbia. Past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company's growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).

Dom Spina, PhD – Director

Obtained his PhD from the University of Western Australia in 1988, & awarded a C.G. Martin Fellowship from the National Health and Research Council of Australia to undertake postdoctoral studies at King's College London (1988–1991). Returning to the United Kingdom in 1994 as a Lecturer in Respiratory Pharmacology in the School of Medicine, Kings College London. He is currently head of Pharmacology and Therapeutics Research within the Institute of Pharmaceutical Science. Dr. Spina is a member of the British Pharmacological Society, American Thoracic Society and the European Respiratory Society.

Donald R. Carlow, MD – Director

Past President and CEO (Jan 1994–Oct 2000) of the British Columbia Cancer Agency (BCCA). Dr. Carlow's efforts led to the development of new cancer centers, as well as laying the groundwork for the BC Cancer Research Center. Dr. Carlow was a member of the board of the Vancouver Island Health Authority, where he chaired the board's health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Dr. Carlow was also a judge for the 3M National Health Care Quality Awards for four years during the 90's.

Veritas Clinical Cannabis Development Pipeline

- Chronic Pain (cancer pain)
- Nausea & Vomiting
- Inflammation
- Muscle Spasms
- Epilepsy
- Post-Traumatic Stress Disorder (PTSD)

Confidence in Highly Credentialed Team of Scientists



- Dr. Michael J.A. Walker, PhD
- Dr. Bernard A. MacLeod, MD
- Dr. Richard A. Wall, PhD
- Dr. Ernest Puil, PhD
- Dr. Andrew Hegle, PhD
- Dr. Thomas Stokes, PhD
- Dr. Ricardo Rivera-Acevedo, PhD



“The strategic alliance that we’ve formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique

strains of medicinal cannabis. These plants will be patent protected for a variety of unmet medical needs. These scientists have indeed the rare skills necessary to make blockbuster medicines, with a history of generating over \$1 billion worth of investor value based on previous drug discoveries.”

- Dr. Franciosi, PhD – CEO